Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

2014-08-27 04:00:24 | BioPortfolio


This study is designed as a three-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare two depot dosage forms, and perform dose ranging of one chosen form in support of a monthly depot dosing regimen. In Phase A, the study is designed to evaluate the safety of a crystalline iloperidone depot formulation. In Phase B, the pharmacokinetic and safety profile of two depot clinical dosage forms will be compared, and one form will be selected for assessment in Phase C. Phase C of this study is designed to define the dose-exposure relationship of the selected form and to provide information that will permit a comparison of the risk-benefit ratio of several doses of the study drug to enable optimal dose selection for later studies.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment




Iloperidone, Iloperidone, Iloperidone, Iloperidone, Iloperidone, Iloperidone, Iloperidone


Novartis Investigative Site
United States





Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T04:00:24-0400

Clinical Trials [1005 Associated Clinical Trials listed on BioPortfolio]

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exace...

Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets

to inspect relevant pharmacokinetic parameters and relative exploitation degree, with fasting and postprandial dosing bioequivalence test under the condition of the human body, provide the...

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

The purpose of this pilot randomized clinical trial is to begin to delineate the pathophysiological changes associated with antipsychotic associated metabolic side effects. The study will ...

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatme...

PubMed Articles [865 Associated PubMed Articles listed on BioPortfolio]

Long-term effects of iloperidone on cerebral dopamine receptor subtypes.

The atypical antipsychotic drug iloperidone has high affinity for a wide range of neurotransmitter receptors including dopaminergic (DA), serotonergic and adrenergic receptors. We examined the long-te...

Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions.

Schizophrenia is associated with increased physical morbidity and early mortality, suggesting that the aging process may be accelerated in schizophrenia. However, the biological underpinnings of these...

Impaired neuropsychological profile in homicide offenders with schizophrenia.

Our ability to predict and prevent homicides committed by individuals with schizophrenia is limited. Cognitive impairments are associated with poorer functional outcome in schizophrenia, possibly also...

Simulated car driving and its association with cognitive abilities in patients with schizophrenia.

Patients with schizophrenia commonly suffer from impairments in various aspects of cognition. These deficits were shown to have detrimental effects on daily life functioning and might also impair car ...

Nurses' Experiences in using Physical Activity as Complementary Treatment in Patients with Schizophrenia.

Schizophrenia is a common disease with a high risk of comorbidity in both psychiatric and somatic diseases. Physical activity is proven effective in reducing symptoms of schizophrenia and increasing o...

Medical and Biotech [MESH] Definitions

A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.

A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.

An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.

A type of schizophrenia characterized by frequent incoherence; marked loosening of associations, or grossly disorganized behavior and flat or grossly inappropriate affect that does not meet the criteria for the catatonic type; associated features include extreme social withdrawal, grimacing, mannerisms, mirror gazing, inappropriate giggling, and other odd behavior. (Dorland, 27th ed)

An antipsychotic agent used in schizophrenia.

More From BioPortfolio on "Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Searches Linking to this Trial